Published April 14, 2022 | Version v2
Journal article Restricted

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhance immune activity: a gene profiling retrospective analysis

Authors/Creators

  • 1. Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Naples, Italy
  • 2. Regina Elena National Cancer Institute, IRCCS, Roma, Lazio, Italy
  • 3. NanoString Technologies, Seattle, USA

Description

Nivolumab is an anti-PD1 antibody approved for the treatment of metastatic melanoma (MM), for which still limited evidence is available on the correlation between drug exposure and patient’s outcomes. In this observational retrospective study we assessed whether nivolumab concentration is associated with treatment response in patients with MM, and if patient’s genetic profile plays a role in this association. We observed a statistically significant correlation between nivolumab serum concentration and clinical outcomes, measured as overall survival and progression free survival. Moreover, patients who reached a clinical response (CR) had significantly higher concentration of nivolumab and presented a distinct genetic signature, with a more marked activation of ICOS and other genes involved in effector T-cells mediated pro-inflammatory pathways.

In conclusion, in patients with MM nivolumab concentration correlates with clinical outcomes and is associated with an increased expression of ICOS and other genes involved in the activation of T effectors cells.

Files

Restricted

The record is publicly accessible, but files are restricted. <a href="https://zenodo.org/account/settings/login?next=https://zenodo.org/records/6586704">Log in</a> to check if you have access.

Request access

If you would like to request access to these files, please fill out the form below.

You need to satisfy these conditions in order for this request to be accepted:

Please specify the purpose of the study

You are currently not logged in. Do you have an account? Log in here